High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine

Timothy Wilkin, Jeannette Y. Lee, Shelly Y. Lensing, Elizabeth A. Stier, Stephen E. Goldstone, J. Michael Berry, Naomi Jay, David M. Aboulafia, Mark H. Einstein, Alfred Saah, Ronald T. Mitsuyasu, Joel M. Palefsky

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P =.01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.

Original languageEnglish (US)
Pages (from-to)75-79
Number of pages5
JournalHIV Clinical Trials
Volume14
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Papillomavirus Vaccines
Multicenter Studies
HIV-1
Clinical Trials
Neoplasms
Anus Neoplasms
Cell Biology
Human papillomavirus 18
Human papillomavirus 16
CD4 Lymphocyte Count
Vaccination
HIV
Biopsy
Therapeutics

Keywords

  • anal infection
  • anal intraepithelial neoplasia
  • HIV-1 infection
  • human papillomavirus
  • male

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Wilkin, T., Lee, J. Y., Lensing, S. Y., Stier, E. A., Goldstone, S. E., Berry, J. M., ... Palefsky, J. M. (2013). High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. HIV Clinical Trials, 14(2), 75-79. https://doi.org/10.1310/hct1402-75

High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. / Wilkin, Timothy; Lee, Jeannette Y.; Lensing, Shelly Y.; Stier, Elizabeth A.; Goldstone, Stephen E.; Berry, J. Michael; Jay, Naomi; Aboulafia, David M.; Einstein, Mark H.; Saah, Alfred; Mitsuyasu, Ronald T.; Palefsky, Joel M.

In: HIV Clinical Trials, Vol. 14, No. 2, 01.01.2013, p. 75-79.

Research output: Contribution to journalArticle

Wilkin, T, Lee, JY, Lensing, SY, Stier, EA, Goldstone, SE, Berry, JM, Jay, N, Aboulafia, DM, Einstein, MH, Saah, A, Mitsuyasu, RT & Palefsky, JM 2013, 'High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine', HIV Clinical Trials, vol. 14, no. 2, pp. 75-79. https://doi.org/10.1310/hct1402-75
Wilkin, Timothy ; Lee, Jeannette Y. ; Lensing, Shelly Y. ; Stier, Elizabeth A. ; Goldstone, Stephen E. ; Berry, J. Michael ; Jay, Naomi ; Aboulafia, David M. ; Einstein, Mark H. ; Saah, Alfred ; Mitsuyasu, Ronald T. ; Palefsky, Joel M. / High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. In: HIV Clinical Trials. 2013 ; Vol. 14, No. 2. pp. 75-79.
@article{9bfed30ed5e241e1b71dd8d996a0a264,
title = "High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine",
abstract = "Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23{\%} and 10{\%}, respectively; abnormal anal cytology was found in 56{\%} and HGAIN in 30{\%}. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38{\%} vs 17{\%}; P =.01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.",
keywords = "anal infection, anal intraepithelial neoplasia, HIV-1 infection, human papillomavirus, male",
author = "Timothy Wilkin and Lee, {Jeannette Y.} and Lensing, {Shelly Y.} and Stier, {Elizabeth A.} and Goldstone, {Stephen E.} and Berry, {J. Michael} and Naomi Jay and Aboulafia, {David M.} and Einstein, {Mark H.} and Alfred Saah and Mitsuyasu, {Ronald T.} and Palefsky, {Joel M.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1310/hct1402-75",
language = "English (US)",
volume = "14",
pages = "75--79",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine

AU - Wilkin, Timothy

AU - Lee, Jeannette Y.

AU - Lensing, Shelly Y.

AU - Stier, Elizabeth A.

AU - Goldstone, Stephen E.

AU - Berry, J. Michael

AU - Jay, Naomi

AU - Aboulafia, David M.

AU - Einstein, Mark H.

AU - Saah, Alfred

AU - Mitsuyasu, Ronald T.

AU - Palefsky, Joel M.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P =.01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.

AB - Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P =.01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.

KW - anal infection

KW - anal intraepithelial neoplasia

KW - HIV-1 infection

KW - human papillomavirus

KW - male

UR - http://www.scopus.com/inward/record.url?scp=84878844175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878844175&partnerID=8YFLogxK

U2 - 10.1310/hct1402-75

DO - 10.1310/hct1402-75

M3 - Article

VL - 14

SP - 75

EP - 79

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 2

ER -